WO2019081468A1 - Energizing food supplement and use thereof - Google Patents
Energizing food supplement and use thereofInfo
- Publication number
- WO2019081468A1 WO2019081468A1 PCT/EP2018/078969 EP2018078969W WO2019081468A1 WO 2019081468 A1 WO2019081468 A1 WO 2019081468A1 EP 2018078969 W EP2018078969 W EP 2018078969W WO 2019081468 A1 WO2019081468 A1 WO 2019081468A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- food supplement
- extract
- vitamin
- supplement according
- taurine
- Prior art date
Links
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 56
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 40
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims abstract description 32
- 239000000284 extract Substances 0.000 claims abstract description 30
- 230000000694 effects Effects 0.000 claims abstract description 27
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 26
- 240000004482 Withania somnifera Species 0.000 claims abstract description 25
- 235000001978 Withania somnifera Nutrition 0.000 claims abstract description 25
- 206010019133 Hangover Diseases 0.000 claims abstract description 20
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229960003080 taurine Drugs 0.000 claims abstract description 20
- 239000009405 Ashwagandha Substances 0.000 claims abstract description 17
- 235000010841 Silybum marianum Nutrition 0.000 claims abstract description 17
- DBRXOUCRJQVYJQ-CKNDUULBSA-N withaferin A Chemical compound C([C@@H]1[C@H]([C@@H]2[C@]3(CC[C@@H]4[C@@]5(C)C(=O)C=C[C@H](O)[C@@]65O[C@@H]6C[C@H]4[C@@H]3CC2)C)C)C(C)=C(CO)C(=O)O1 DBRXOUCRJQVYJQ-CKNDUULBSA-N 0.000 claims abstract description 17
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229960001948 caffeine Drugs 0.000 claims abstract description 16
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims abstract description 16
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 14
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 14
- 241000124033 Salix Species 0.000 claims abstract description 13
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 13
- 229930091371 Fructose Natural products 0.000 claims abstract description 11
- 239000005715 Fructose Substances 0.000 claims abstract description 11
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims abstract description 11
- 229930003779 Vitamin B12 Natural products 0.000 claims abstract description 10
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims abstract description 10
- 229960003624 creatine Drugs 0.000 claims abstract description 10
- 239000006046 creatine Substances 0.000 claims abstract description 10
- 235000019163 vitamin B12 Nutrition 0.000 claims abstract description 10
- 239000011715 vitamin B12 Substances 0.000 claims abstract description 10
- 241000320380 Silybum Species 0.000 claims abstract description 9
- 241001278097 Salix alba Species 0.000 claims abstract description 8
- 244000272459 Silybum marianum Species 0.000 claims abstract description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 8
- SASUFNRGCZMRFD-JCUIILOWSA-N withanolide D Chemical compound C1C(C)=C(C)C(=O)O[C@H]1[C@](C)(O)[C@@H]1[C@@]2(C)CC[C@@H]3[C@@]4(C)C(=O)C=C[C@H](O)[C@@]54O[C@@H]5C[C@H]3[C@@H]2CC1 SASUFNRGCZMRFD-JCUIILOWSA-N 0.000 claims abstract description 8
- 230000002265 prevention Effects 0.000 claims abstract description 6
- 206010019233 Headaches Diseases 0.000 claims description 9
- 231100000869 headache Toxicity 0.000 claims description 9
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 claims description 7
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 claims description 7
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 claims description 7
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 claims description 7
- 229940120668 salicin Drugs 0.000 claims description 7
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 claims description 7
- 229960004245 silymarin Drugs 0.000 claims description 7
- 235000017700 silymarin Nutrition 0.000 claims description 7
- 208000016255 tiredness Diseases 0.000 claims description 7
- 230000003867 tiredness Effects 0.000 claims description 7
- PQZVBIJEPVKNOZ-PCLZMVHQSA-N (2R)-2-[(1S)-1-hydroxy-1-[(5R,6R,8R,9S,10R,13S,14R,17S)-5,6,14,17-tetrahydroxy-10,13-dimethyl-1-oxo-6,7,8,9,11,12,15,16-octahydro-4H-cyclopenta[a]phenanthren-17-yl]ethyl]-4,5-dimethyl-2,3-dihydropyran-6-one Chemical class C1C(C)=C(C)C(=O)O[C@H]1[C@](C)(O)[C@@]1(O)[C@@]2(C)CC[C@@H]3[C@@]4(C)C(=O)C=CC[C@]4(O)[C@H](O)C[C@H]3[C@]2(O)CC1 PQZVBIJEPVKNOZ-PCLZMVHQSA-N 0.000 claims description 5
- 206010028813 Nausea Diseases 0.000 claims description 5
- JAVFSUSPBIUPLW-QEWGJZFKSA-N Withanolide Natural products O=C1[C@@H](C)[C@H](C)C[C@H]([C@@H](C)[C@@H]2[C@@]3(C)[C@H]([C@@H]4[C@@H]([C@]5(C)[C@@H](CC4)CCCC5)CC3)CC2)O1 JAVFSUSPBIUPLW-QEWGJZFKSA-N 0.000 claims description 5
- 230000008693 nausea Effects 0.000 claims description 5
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 3
- 239000004383 Steviol glycoside Substances 0.000 claims description 3
- 239000004376 Sucralose Substances 0.000 claims description 3
- 206010022437 insomnia Diseases 0.000 claims description 3
- 230000003204 osmotic effect Effects 0.000 claims description 3
- 239000004302 potassium sorbate Substances 0.000 claims description 3
- 235000010241 potassium sorbate Nutrition 0.000 claims description 3
- 229940069338 potassium sorbate Drugs 0.000 claims description 3
- 230000035945 sensitivity Effects 0.000 claims description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 3
- 239000004299 sodium benzoate Substances 0.000 claims description 3
- 235000010234 sodium benzoate Nutrition 0.000 claims description 3
- 229930182488 steviol glycoside Natural products 0.000 claims description 3
- 235000019411 steviol glycoside Nutrition 0.000 claims description 3
- 150000008144 steviol glycosides Chemical class 0.000 claims description 3
- 235000019202 steviosides Nutrition 0.000 claims description 3
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 3
- 235000019408 sucralose Nutrition 0.000 claims description 3
- 235000010493 xanthan gum Nutrition 0.000 claims description 3
- 229920001285 xanthan gum Polymers 0.000 claims description 3
- 239000000230 xanthan gum Substances 0.000 claims description 3
- 229940082509 xanthan gum Drugs 0.000 claims description 3
- 229930003270 Vitamin B Natural products 0.000 claims description 2
- 229960003885 sodium benzoate Drugs 0.000 claims description 2
- 235000019156 vitamin B Nutrition 0.000 claims description 2
- 239000011720 vitamin B Substances 0.000 claims description 2
- 239000013589 supplement Substances 0.000 abstract description 7
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 abstract description 5
- 229960003495 thiamine Drugs 0.000 abstract description 2
- 229930003451 Vitamin B1 Natural products 0.000 abstract 1
- 229960002737 fructose Drugs 0.000 abstract 1
- 235000010374 vitamin B1 Nutrition 0.000 abstract 1
- 239000011691 vitamin B1 Substances 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 14
- 230000009471 action Effects 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 7
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 229940096421 milk thistle extract Drugs 0.000 description 6
- 235000020727 milk thistle extract Nutrition 0.000 description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 6
- 230000035987 intoxication Effects 0.000 description 5
- 231100000566 intoxication Toxicity 0.000 description 5
- 210000000653 nervous system Anatomy 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 206010016256 fatigue Diseases 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 208000013016 Hypoglycemia Diseases 0.000 description 3
- 206010047141 Vasodilatation Diseases 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 230000037149 energy metabolism Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 229960004889 salicylic acid Drugs 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000024883 vasodilation Effects 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 206010001605 Alcohol poisoning Diseases 0.000 description 2
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000036626 alertness Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000004110 gluconeogenesis Effects 0.000 description 2
- 230000002443 hepatoprotective effect Effects 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229930182487 phenolic glycoside Natural products 0.000 description 2
- 150000007950 phenolic glycosides Chemical class 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229940076788 pyruvate Drugs 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- MEJYXFHCRXAUIL-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;hydrate Chemical compound O.NC(=N)N(C)CC(O)=O MEJYXFHCRXAUIL-UHFFFAOYSA-N 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- 206010013142 Disinhibition Diseases 0.000 description 1
- 241001539473 Euphoria Species 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010049976 Impatience Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002535 acidifier Substances 0.000 description 1
- 229940095602 acidifiers Drugs 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 229940093797 bioflavonoids Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229960004826 creatine monohydrate Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 208000016253 exhaustion Diseases 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 208000018883 loss of balance Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 150000004682 monohydrates Chemical group 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000065 osmolyte Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229950007002 phosphocreatine Drugs 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000002438 stress hormone Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to an energizing food supplement, particularly for the prevention and treatment of the effects of a hangover.
- the present invention also relates to the use of this energizing supplement for the prevention and treatment of the effects of a hangover such as, for example, tiredness, headache, nausea, difficulty concentrating, sensitivity to light and noise, and insomnia.
- a hangover such as, for example, tiredness, headache, nausea, difficulty concentrating, sensitivity to light and noise, and insomnia.
- Alcohol An excessive intake of alcohol (ethanol) produces the symptoms of alcohol intoxication such as initial euphoria, loss of inhibitions, slurred or confused speech (typically associated with a blood alcohol level of 0.2-0.4 g/L), vomiting, loss of balance (0.5-1.5 g/L), and even coma in more serious cases (higher than 4.0-5.0 g/L).
- Intoxication is the result of the introduction of an amount of alcohol that is greater than the amount that can be metabolized and excreted by the organism.
- the after-effects that are present upon awakening after intoxication from alcoholic beverages are referred to as a "hangover" and they include: dehydration, headache, hypoglycemia, exhaustion, and feelings of nausea.
- one of the symptoms of a hangover, dehydration is caused by inhibition of the vasopressin hormone by acetaldehyde in the brain, which impedes the concentration of urine and therefore causes a considerable diuretic effect.
- the hypoglycemia is caused by a slowing of gluconeogenesis in the liver, owing to the excess of NADH produced during the metabolization of the ethanol and the subsequent conversion of pyruvic acid to lactic acid which accumulates in the tissues, another factor that results from the breakdown of ethanol.
- the ethanol is in fact converted to acetaldehyde by the alcohol dehydrogenase enzyme and the acetaldehyde in turn is converted to acetate by the acetaldehyde dehydrogenase enzyme.
- Acetaldehyde and acetate are highly toxic; in particular acetaldehyde is about 30 times more toxic than alcohol per se; therefore it is the main cause of the effects of a hangover.
- VLDLs very-low-density lipoproteins
- the aim of the present invention is therefore to provide a food supplement that helps to alleviate the effects of a hangover, thus helping the sufferer to faster return to a normal level of psycho- physical functionality.
- Another object of the present invention is to provide a food supplement that has a protective function on the liver.
- Another object of the present invention is to provide a food supplement that favors physical and mental wellness and positively influences the cognitive processes.
- Another object of the present invention is to provide a food supplement that is easy to take and which has the desired effects within a short time.
- an energizing food supplement particularly for preventing or treating the effects of a hangover, which comprises:
- the aims and the objects of the present invention are also achieved by the above mentioned energizing food supplement for use in the prevention and treatment of the effects of the effects of a hangover.
- the present invention relates to an energizing food supplement, particularly for preventing or treating the effects of a hangover, as defined above and characterized in that it comprises an association of active ingredients constituted by creatine, taurine, caffeine, ashwagandha (withania somnifera) extract, milk thistle (silybum marianum) extract, willow (salix alba) extract, vitamin B12, vitamin B6, vitamin Bl , and fructose.
- active ingredients constituted by creatine, taurine, caffeine, ashwagandha (withania somnifera) extract, milk thistle (silybum marianum) extract, willow (salix alba) extract, vitamin B12, vitamin B6, vitamin Bl , and fructose.
- Creatine which is converted to phosphocreatine in the body, facilitates the use of oxygen and the formation of ATP and therefore of energy used in intense efforts by muscles. It therefore contributes to counteract exhaustion.
- the food supplement of the present invention comprises creatine in a quantity of 0.2 mg/mL to 40 mg/mL.
- the food supplement of the present invention comprises 10 mg/mL of creatine.
- the creatine is in monohydrate form.
- Taurine is one of the osmolytes that regulate cellular volume. Therefore, the ingestion of taurine by dehydrated subjects after the ingestion of alcohol stimulates the introduction of water into the cells. Taurine also has an important physiological role, as it is a necessary component in the synthesis of bile acids, it improves the use of sugars and it increases the effectiveness of insulin, thus facilitating a rapid use of the fructose present in the supplement.
- Taurine performs several actions on the body: it improves the metabolism of lipids and of sugars at the hepatic level; it facilitates the renal excretion of toxic substances; it facilitates the contractility of the skeletal muscle and of the heart, increasing its cardiac output. It is therefore recommended for increasing physiological performance and reducing recovery times.
- taurine is in fact an amino acid that calms the nervous system, because it supports the production of gamma-aminobutyric acid (GABA). It can facilitate the management of anxiety, potentially counteracting stress hormones. Its use as an ingredient in the formulation of the supplement facilitates temperature control and improves concentration.
- the food supplement of the present invention comprises taurine in a quantity of 0.2 mg/mL to 40 mg/mL. In a preferred embodiment, the food supplement of the present invention comprises 10 mg/mL of taurine.
- Caffeine has many effects on the human body and is capable of reducing the sense of tiredness, increasing alertness and stimulating intestinal motility, promoting a general state of wellbeing, both physiological and neurological.
- Caffeine has a stimulating action on the central nervous system (CNS), on the cardiovascular apparatus, on the release of catecholamines, on the synthesis of gastric acid and on the metabolism in general. Furthermore, caffeine produces an increase in the state of wakefulness and of alertness, of the capacity for concentration, and general enhancement of physical and mental efficiency. As well as the excitatory activity, which is very good for counteracting the exhaustion typical of a hangover, caffeine also has a vasoconstricting action, which produces a slight analgesic effect, and can therefore be exploited to act against the headache caused by vasodilatation in the brain.
- the food supplement of the present invention comprises caffeine in a quantity of 0.2 mg/mL to 40 mg/mL. In a preferred embodiment, the food supplement of the present invention comprises 8 mg/mL of caffeine.
- the food supplement of the present invention also comprises ashwagandha (withania somnifera) root extract in its active ingredients.
- Ashwagandha has neuro-protective properties and an adaptogenic and anxiolytic activity that can help the subject to overcome the phenomena of anxiety and depression that are typical of the effects of a hangover, owing to the action of alcohol and acetaldehyde on the central nervous system.
- Most of the properties ascribed to ashwagandha are in particular due to the withanolides (steroidal lactones) contained in it.
- Ashwagandha also has an anticonvulsant activity, which is probably related to an interaction with the receptor of the barbiturates present in the receptor for GABA.
- Ashwagandha also improves mood tone, thus reducing the irritability and impatience that are typical of the effects of a hangover.
- the food supplement of the present invention comprises ashwagandha extract in a quantity of 0.04 mg/mL to 20 mg/mL, preferably with a content of 0.002 mg/mL to 1.2 mg/mL of withanolides.
- the food supplement of the present invention comprises 1.6 mg/mL of ashwagandha extract, preferably with a content of 0.08 mg/mL of withanolides.
- the ashwagandha extract can for example be the KSM-66® product marketed by Ixoreal Biomed.
- Milk thistle (silybum marianum) fruit extract has effects on the digestive function and on the hepatic function, and it carries out a purifying and antioxidant function.
- silymarin a complex of bioflavonoids called flavonolignans contained in milk thistle extract, carries out a defense function against many toxic substances, including alcohol.
- Milk thistle extract is also an antioxidant that prevents the oxidation of lipids and the destruction of cellular membranes.
- milk thistle extract The hepatoprotective effect of milk thistle extract is given by the acceleration of the liver regeneration process. Furthermore, milk thistle extract increases the metabolic activity of the hepatic cells. Therefore it facilitates the excretory system and detoxification in general. In effect, the silymarin contained in it stimulates protein synthesis and regeneration of the hepatic parenchyma.
- the food supplement of the present invention comprises milk thistle extract in a quantity of 0.04 mg/mL to 20 mg/mL, preferably with a content of 0.032 mg/mL to 16 mg/mL of silymarin.
- the food supplement of the present invention comprises 0.2 mg/mL of milk thistle extract, preferably with a content of 0.16 mg/mL of silymarin.
- Willow (salix alba) extract by virtue of its anti-inflammatory activity, counteracts the headache owing to the generalized inflammation in the brain caused by alcohol intoxication and localized vasodilatation.
- Willow extract is rich in tannins, flavonoids, glycosides and esters which, by hydrolysis, produce salicylic acid, in particular from a phenolic glycoside called salicin.
- the anti-inflammatory activity of willow is given not just by salicin, but also by other phenolic glycosides that act as prodrugs of salicylic acid.
- Salicylic acid further inhibits the formation of inflammatory mediators.
- salicin does not irreversibly inhibit platelet aggregation.
- the food supplement of the present invention comprises willow extract in a quantity of 0.04 mg/mL to 20 mg/mL, preferably with a content of 0.006 mg/mL to 3 mg/mL of salicin.
- the food supplement of the present invention comprises 0.4 mg/mL of willow extract, preferably with a content of 0.06 mg/mL of salicin.
- vitamin B12 contributes to energy metabolism and to the reduction of tiredness and fatigue, to the operation of the nervous system, to normal psychological functioning, to the metabolism of homocysteine and to the formation of red blood cells, it intervenes in the process of cell division, and it contributes to the functioning of the immune system.
- Vitamin B6 has an antiemetic action, it counteracts feelings of nausea, and it restores hormonal activity altered by the effects of alcohol.
- Vitamin B6 further contributes to the normal synthesis of cysteine, to achieving normal energy metabolism, to the operation of the nervous system, to the metabolism of homocysteine, to the metabolism of proteins and of glycogen, and to psychological functioning. Vitamin B6 also contributes to the formation of red blood cells, to the functioning of the immune system, and to reducing tiredness and fatigue.
- vitamin B6 contributes to the regulation of hormonal activity.
- Vitamin Bl (thiamine) contributes to energy metabolism, to cardiac function, to the operation of the nervous system and to psychological functioning.
- the dosage of the vitamins in the supplement of the present invention is particularly significant with respect to the Nutrient Reference Value (NRV).
- NSV Nutrient Reference Value
- Their action is very rapid as they are water-soluble vitamins, and the doses used in the present invention are safe as well as effective since, although high, such doses are lower than the maximum recommended daily intake and any excess can be easily eliminated by the body.
- the food supplement of the present invention comprises vitamin B12 in a quantity of 0.04 ⁇ g/mL to 8 ⁇ g/mL. In a preferred embodiment, the food supplement of the present invention comprises 0.6 ⁇ g/mL of vitamin B12.
- the food supplement of the present invention comprises vitamin B6 in a quantity of 0.04 mg/mL to 6 mg/mL. In a preferred embodiment, the food supplement of the present invention comprises 168 ⁇ g/mL of vitamin B6.
- the food supplement of the present invention comprises vitamin Bl in a quantity of 0.04 mg/mL to 4 mg/mL. In a preferred embodiment, the food supplement of the present invention comprises 99 ⁇ g/mL of vitamin Bl .
- the fructose contained in the formulation of the supplement according to the invention is rapidly absorbed and converted to glucose, in this manner counteracting the hypoglycemia.
- the food supplement of the present invention comprises fructose in a quantity of 10 mg/mL to 400 mg/mL. In a preferred embodiment, the food supplement of the present invention comprises 200 mg/mL of fructose.
- the food supplement according to the invention can furthermore contain one or more excipients.
- excipients can be selected from the group consisting of flavorings (for example pear flavoring), thickeners (for example xanthan gum, preferably in an amount of about 1-100 mg/mL i.e. 0.1-10% w/v, more preferably 5 mg/mL i.e. 0.5% w/v), acidifiers (for example citric acid), preservatives (for example potassium sorbate and/or sodium benzoate) and sweeteners (for example sucralose and/or steviol glycosides).
- flavorings for example pear flavoring
- thickeners for example xanthan gum, preferably in an amount of about 1-100 mg/mL i.e. 0.1-10% w/v, more preferably 5 mg/mL i.e. 0.5% w/v
- acidifiers for example citric acid
- preservatives for example potassium sorbate and/or sodium benzoate
- the active ingredients and any excipients of the supplement according to the present invention are contained in a physiologically acceptable carrier, preferably water, for example osmotic water.
- the energizing food supplement according to the invention comprises, more preferably is essentially constituted by, and even more preferably is constituted by:
- excipients consisting of a combination of an aroma, xanthan gum, potassium sorbate, sodium benzoate, sucralose and steviol glycosides,
- a physiologically acceptable vehicle constituted by osmotic water.
- the energizing food supplement according to the invention can be formulated in a ready-to-use solution.
- the food supplement according to the invention can be supplied in phials, or other container suitable for use, preferably in a 25 mL dose.
- Another aspect of the present invention relates to the energizing food supplement according to the invention for use in the prevention and treatment of the effects of a hangover.
- the effects of a hangover comprise tiredness, headache, nausea, difficulty concentrating, sensitivity to light and noise, and insomnia.
- the energizing food supplement is taken preferably upon awakening, preferably with a 25 mL dose.
- the present invention also relates to a method for preventing and treating the effects of a hangover by way of the administration to a subject who needs it of an energizing food supplement as described herein.
- the energizing food supplement according to the invention is effective in alleviating the effects of a hangover, such as in particular tiredness, headache and ability to concentrate, by virtue of the combined action of its active ingredients.
- the food supplement according to the invention counteracts headache by virtue of the vasoconstricting action induced by the caffeine, helps rapidly to reactivate the metabolism by virtue of the high doses of vitamins B6, B 12 and Bl, counteracts dehydration by virtue of the taurine, reduces pain and headache by virtue of the action of the willow, and helps to counteract anxiety and stress by contributing to a rapid restoration of mental and physical wellness by virtue of the ashwagandha.
- the food supplement according to the invention has a hepatoprotective action, by virtue of the taurine which contributes to the liver function, and the silymarin, which counteracts the damage caused by alcohol.
- the taurine and the milk thistle eliminate the free radicals due to intoxication and have a protective action on the liver, facilitating its activity.
Abstract
An energizing food supplement that comprises creatine, taurine, caffeine, ashwagandha (withania somnifera) extract, milk thistle (silybum marianum) extract, willow (salix alba) extract, vitamin B12, vitamin B6, vitamin B1, fructose and optionally one or more excipients, in a physiologically acceptable carrier. The invention further relates to such supplement for use in the prevention and treatment of the effects of a hangover.
Description
ENERGIZING FOOD SUPPLEMENT AND USE THEREOF
The present invention relates to an energizing food supplement, particularly for the prevention and treatment of the effects of a hangover.
The present invention also relates to the use of this energizing supplement for the prevention and treatment of the effects of a hangover such as, for example, tiredness, headache, nausea, difficulty concentrating, sensitivity to light and noise, and insomnia.
An excessive intake of alcohol (ethanol) produces the symptoms of alcohol intoxication such as initial euphoria, loss of inhibitions, slurred or confused speech (typically associated with a blood alcohol level of 0.2-0.4 g/L), vomiting, loss of balance (0.5-1.5 g/L), and even coma in more serious cases (higher than 4.0-5.0 g/L).
Intoxication is the result of the introduction of an amount of alcohol that is greater than the amount that can be metabolized and excreted by the organism. The after-effects that are present upon awakening after intoxication from alcoholic beverages are referred to as a "hangover" and they include: dehydration, headache, hypoglycemia, exhaustion, and feelings of nausea.
In particular, one of the symptoms of a hangover, dehydration, is caused by inhibition of the vasopressin hormone by acetaldehyde in the brain, which impedes the concentration of urine and therefore causes a considerable diuretic effect.
The hypoglycemia is caused by a slowing of gluconeogenesis in the liver, owing to the excess of NADH produced during the metabolization of the ethanol and the subsequent conversion of pyruvic acid to lactic acid which accumulates in the tissues, another factor that results from the breakdown of ethanol. The ethanol is in fact converted to acetaldehyde by the alcohol dehydrogenase enzyme and the acetaldehyde in turn is converted to acetate by the acetaldehyde dehydrogenase enzyme. Acetaldehyde and acetate are highly toxic; in particular acetaldehyde is about 30 times more
toxic than alcohol per se; therefore it is the main cause of the effects of a hangover.
The aforementioned two reactions also require the conversion of NAD+ to NADH. With the exceeding NADH, the reaction of the lactate dehydrogenase enzyme leads to the production of lactate from pyruvate (the final product of glycolysis) in order to regenerate the necessary NAD+. This deviates the pyruvate from other routes, such as gluconeogenesis, thus interfering with the ability of the liver to resupply tissues with glucose, especially the brain. Since glucose is the main energy source of the brain, this lack of glucose contributes to symptoms such as fatigue, weakness, mood swings and decrease in attention and in concentration.
The feeling of exhaustion is the result of the accumulation of triglycerides and of the formation of ketone bodies resulting from the elimination of acetic acid. This is reflected in the increase in the hepatic synthesis of very-low-density lipoproteins (VLDLs) and causes them to be deposited in the liver (hepatic steatosis), and also the increase in their plasma concentration.
Furthermore, the generalized effect of intoxication by acetaldehyde in the central nervous system and in the brain causes vasodilatation and can induce nausea and vomiting.
Faced with the more or less debilitating consequences owing to the consumption of alcohol, the aim of the present invention is therefore to provide a food supplement that helps to alleviate the effects of a hangover, thus helping the sufferer to faster return to a normal level of psycho- physical functionality.
Another object of the present invention is to provide a food supplement that has a protective function on the liver.
Another object of the present invention is to provide a food supplement that favors physical and mental wellness and positively influences the cognitive processes.
Another object of the present invention is to provide a food supplement that is easy to take and which has the desired effects within a short time.
This aim and these and other objects which will become better apparent hereinafter are achieved by an energizing food supplement, particularly for preventing or treating the effects of a hangover, which comprises:
- 0.2 mg/mL to 40 mg/mL of creatine,
- 0.2 mg/mL to 40 mg/mL of taurine,
- 0.2 mg/mL to 40 mg/mL of caffeine,
- 0.04 mg/mL to 20 mg/mL of ashwagandha (Withania somnifera) extract,
- 0.04 mg/mL to 20 mg/mL of milk thistle (Silybum marianum) extract,
- 0.04 mg/mL to 20 mg/mL of willow (Salix alba) extract,
- 0.04 μg/mL to 8 μg/mL of vitamin B12,
- 0.04 mg/mL to 6 mg/mL of vitamin B6,
- 0.04 mg/mL to 4 mg/mL of vitamin B l,
- 10 mg/mL to 400 mg/mL of fructose, and
optionally one or more excipients, in a physiologically acceptable carrier.
The aims and the objects of the present invention are also achieved by the above mentioned energizing food supplement for use in the prevention and treatment of the effects of the effects of a hangover.
Further characteristics and advantages of the invention will become better apparent from the detailed description that follows.
The present invention relates to an energizing food supplement, particularly for preventing or treating the effects of a hangover, as defined above and characterized in that it comprises an association of active ingredients constituted by creatine, taurine, caffeine, ashwagandha (withania
somnifera) extract, milk thistle (silybum marianum) extract, willow (salix alba) extract, vitamin B12, vitamin B6, vitamin Bl , and fructose.
Creatine, which is converted to phosphocreatine in the body, facilitates the use of oxygen and the formation of ATP and therefore of energy used in intense efforts by muscles. It therefore contributes to counteract exhaustion.
The food supplement of the present invention comprises creatine in a quantity of 0.2 mg/mL to 40 mg/mL. In a preferred embodiment, the food supplement of the present invention comprises 10 mg/mL of creatine. Preferably, the creatine is in monohydrate form.
Taurine is one of the osmolytes that regulate cellular volume. Therefore, the ingestion of taurine by dehydrated subjects after the ingestion of alcohol stimulates the introduction of water into the cells. Taurine also has an important physiological role, as it is a necessary component in the synthesis of bile acids, it improves the use of sugars and it increases the effectiveness of insulin, thus facilitating a rapid use of the fructose present in the supplement.
Taurine performs several actions on the body: it improves the metabolism of lipids and of sugars at the hepatic level; it facilitates the renal excretion of toxic substances; it facilitates the contractility of the skeletal muscle and of the heart, increasing its cardiac output. It is therefore recommended for increasing physiological performance and reducing recovery times.
Some studies on the use of taurine have shown a role in reducing muscular fatigue, leading to benefits in temperature control (helping to stabilize body temperature during physical activity) and in concentration. It is often incorrectly claimed that taurine is an energy stimulant, but in reality it can have an opposite action, since it is involved in inhibiting the exciter neurons of the brain, which rather makes it a relaxant. Taurine is in fact an amino acid that calms the nervous system, because it supports the
production of gamma-aminobutyric acid (GABA). It can facilitate the management of anxiety, potentially counteracting stress hormones. Its use as an ingredient in the formulation of the supplement facilitates temperature control and improves concentration.
The food supplement of the present invention comprises taurine in a quantity of 0.2 mg/mL to 40 mg/mL. In a preferred embodiment, the food supplement of the present invention comprises 10 mg/mL of taurine.
Caffeine has many effects on the human body and is capable of reducing the sense of tiredness, increasing alertness and stimulating intestinal motility, promoting a general state of wellbeing, both physiological and neurological.
Caffeine has a stimulating action on the central nervous system (CNS), on the cardiovascular apparatus, on the release of catecholamines, on the synthesis of gastric acid and on the metabolism in general. Furthermore, caffeine produces an increase in the state of wakefulness and of alertness, of the capacity for concentration, and general enhancement of physical and mental efficiency. As well as the excitatory activity, which is very good for counteracting the exhaustion typical of a hangover, caffeine also has a vasoconstricting action, which produces a slight analgesic effect, and can therefore be exploited to act against the headache caused by vasodilatation in the brain.
The activity of caffeine is supported by the inotrope action of taurine which, like caffeine, acts on the muscles and on the nervous system.
The food supplement of the present invention comprises caffeine in a quantity of 0.2 mg/mL to 40 mg/mL. In a preferred embodiment, the food supplement of the present invention comprises 8 mg/mL of caffeine.
The food supplement of the present invention also comprises ashwagandha (withania somnifera) root extract in its active ingredients. Ashwagandha has neuro-protective properties and an adaptogenic and anxiolytic activity that can help the subject to overcome the phenomena of
anxiety and depression that are typical of the effects of a hangover, owing to the action of alcohol and acetaldehyde on the central nervous system. Most of the properties ascribed to ashwagandha are in particular due to the withanolides (steroidal lactones) contained in it.
At the base of the adaptogenic properties of ashwagandha there seems to be an inhibition of the up-regulation of the dopaminergic receptors in the striate body which is induced by stress, for example the stress owing to intoxication by alcohol.
Ashwagandha also has an anticonvulsant activity, which is probably related to an interaction with the receptor of the barbiturates present in the receptor for GABA.
Ashwagandha also improves mood tone, thus reducing the irritability and impatience that are typical of the effects of a hangover.
The food supplement of the present invention comprises ashwagandha extract in a quantity of 0.04 mg/mL to 20 mg/mL, preferably with a content of 0.002 mg/mL to 1.2 mg/mL of withanolides. In a preferred embodiment, the food supplement of the present invention comprises 1.6 mg/mL of ashwagandha extract, preferably with a content of 0.08 mg/mL of withanolides. The ashwagandha extract can for example be the KSM-66® product marketed by Ixoreal Biomed.
Milk thistle (silybum marianum) fruit extract has effects on the digestive function and on the hepatic function, and it carries out a purifying and antioxidant function. In particular, silymarin, a complex of bioflavonoids called flavonolignans contained in milk thistle extract, carries out a defense function against many toxic substances, including alcohol. Milk thistle extract is also an antioxidant that prevents the oxidation of lipids and the destruction of cellular membranes.
The hepatoprotective effect of milk thistle extract is given by the acceleration of the liver regeneration process. Furthermore, milk thistle extract increases the metabolic activity of the hepatic cells. Therefore it
facilitates the excretory system and detoxification in general. In effect, the silymarin contained in it stimulates protein synthesis and regeneration of the hepatic parenchyma.
The food supplement of the present invention comprises milk thistle extract in a quantity of 0.04 mg/mL to 20 mg/mL, preferably with a content of 0.032 mg/mL to 16 mg/mL of silymarin. In a preferred embodiment, the food supplement of the present invention comprises 0.2 mg/mL of milk thistle extract, preferably with a content of 0.16 mg/mL of silymarin.
Willow (salix alba) extract, by virtue of its anti-inflammatory activity, counteracts the headache owing to the generalized inflammation in the brain caused by alcohol intoxication and localized vasodilatation.
Willow extract is rich in tannins, flavonoids, glycosides and esters which, by hydrolysis, produce salicylic acid, in particular from a phenolic glycoside called salicin. The anti-inflammatory activity of willow is given not just by salicin, but also by other phenolic glycosides that act as prodrugs of salicylic acid. Salicylic acid further inhibits the formation of inflammatory mediators. However, unlike aspirin (acetylsalicylic acid), salicin does not irreversibly inhibit platelet aggregation.
The food supplement of the present invention comprises willow extract in a quantity of 0.04 mg/mL to 20 mg/mL, preferably with a content of 0.006 mg/mL to 3 mg/mL of salicin. In a preferred embodiment, the food supplement of the present invention comprises 0.4 mg/mL of willow extract, preferably with a content of 0.06 mg/mL of salicin.
B group vitamins activate the metabolism and counteract the feeling of exhaustion.
In particular, vitamin B12 contributes to energy metabolism and to the reduction of tiredness and fatigue, to the operation of the nervous system, to normal psychological functioning, to the metabolism of homocysteine and to the formation of red blood cells, it intervenes in the process of cell division, and it contributes to the functioning of the immune system.
Vitamin B6 has an antiemetic action, it counteracts feelings of nausea, and it restores hormonal activity altered by the effects of alcohol. Vitamin B6 further contributes to the normal synthesis of cysteine, to achieving normal energy metabolism, to the operation of the nervous system, to the metabolism of homocysteine, to the metabolism of proteins and of glycogen, and to psychological functioning. Vitamin B6 also contributes to the formation of red blood cells, to the functioning of the immune system, and to reducing tiredness and fatigue. Finally, vitamin B6 contributes to the regulation of hormonal activity.
Vitamin Bl (thiamine) contributes to energy metabolism, to cardiac function, to the operation of the nervous system and to psychological functioning.
The dosage of the vitamins in the supplement of the present invention is particularly significant with respect to the Nutrient Reference Value (NRV). Their action is very rapid as they are water-soluble vitamins, and the doses used in the present invention are safe as well as effective since, although high, such doses are lower than the maximum recommended daily intake and any excess can be easily eliminated by the body.
The food supplement of the present invention comprises vitamin B12 in a quantity of 0.04 μg/mL to 8 μg/mL. In a preferred embodiment, the food supplement of the present invention comprises 0.6 μg/mL of vitamin B12.
The food supplement of the present invention comprises vitamin B6 in a quantity of 0.04 mg/mL to 6 mg/mL. In a preferred embodiment, the food supplement of the present invention comprises 168 μg/mL of vitamin B6.
The food supplement of the present invention comprises vitamin Bl in a quantity of 0.04 mg/mL to 4 mg/mL. In a preferred embodiment, the food supplement of the present invention comprises 99 μg/mL of vitamin Bl .
The fructose contained in the formulation of the supplement according to the invention is rapidly absorbed and converted to glucose, in this manner counteracting the hypoglycemia.
The food supplement of the present invention comprises fructose in a quantity of 10 mg/mL to 400 mg/mL. In a preferred embodiment, the food supplement of the present invention comprises 200 mg/mL of fructose.
The food supplement according to the invention can furthermore contain one or more excipients. Such excipients can be selected from the group consisting of flavorings (for example pear flavoring), thickeners (for example xanthan gum, preferably in an amount of about 1-100 mg/mL i.e. 0.1-10% w/v, more preferably 5 mg/mL i.e. 0.5% w/v), acidifiers (for example citric acid), preservatives (for example potassium sorbate and/or sodium benzoate) and sweeteners (for example sucralose and/or steviol glycosides).
The active ingredients and any excipients of the supplement according to the present invention are contained in a physiologically acceptable carrier, preferably water, for example osmotic water.
In a preferred embodiment, the energizing food supplement according to the invention comprises, more preferably is essentially constituted by, and even more preferably is constituted by:
- 10 mg/mL of creatine monohydrate,
- 10 mg/mL of taurine,
- 8 mg/mL of caffeine,
- 1.6 mg/mL of ashwagandha (Withania somnifera) extract, of which 0.08 mg/mL withanolides,
- 0.2 mg/mL of milk thistle (Silybum marianum) extract, of which 0.16 mg/mL silymarin,
- 0.4 mg/mL of willow (Salix alba) extract, of which 0.06 mg/mL salicin,
- 0.6 μg/mL of vitamin B12,
- 168 μg/mL of vitamin B6,
- 99 μg/mL of vitamin B 1 ,
- 200 mg/mL of fructose, and
- excipients consisting of a combination of an aroma, xanthan gum, potassium sorbate, sodium benzoate, sucralose and steviol glycosides,
in a physiologically acceptable vehicle constituted by osmotic water.
Preferably the energizing food supplement according to the invention can be formulated in a ready-to-use solution. In particular, the food supplement according to the invention can be supplied in phials, or other container suitable for use, preferably in a 25 mL dose.
Another aspect of the present invention relates to the energizing food supplement according to the invention for use in the prevention and treatment of the effects of a hangover. In particular, the effects of a hangover comprise tiredness, headache, nausea, difficulty concentrating, sensitivity to light and noise, and insomnia.
The energizing food supplement is taken preferably upon awakening, preferably with a 25 mL dose.
Within this aspect, the present invention also relates to a method for preventing and treating the effects of a hangover by way of the administration to a subject who needs it of an energizing food supplement as described herein.
In practice it has been found that the energizing food supplement according to the invention is effective in alleviating the effects of a hangover, such as in particular tiredness, headache and ability to concentrate, by virtue of the combined action of its active ingredients.
In particular, the food supplement according to the invention counteracts headache by virtue of the vasoconstricting action induced by the caffeine, helps rapidly to reactivate the metabolism by virtue of the high doses of vitamins B6, B 12 and Bl, counteracts dehydration by virtue of the taurine, reduces pain and headache by virtue of the action of the willow, and
helps to counteract anxiety and stress by contributing to a rapid restoration of mental and physical wellness by virtue of the ashwagandha.
Furthermore, the food supplement according to the invention has a hepatoprotective action, by virtue of the taurine which contributes to the liver function, and the silymarin, which counteracts the damage caused by alcohol. The taurine and the milk thistle eliminate the free radicals due to intoxication and have a protective action on the liver, facilitating its activity.
The disclosures in Italian Patent Application No. 102017000119556 from which this application claims priority are incorporated herein by reference.
Claims
1. An energizing food supplement, particularly for preventing or treating the effects of a hangover, which comprises:
- 0.2 mg/mL to 40 mg/mL of creatine,
- 0.2 mg/mL to 40 mg/mL of taurine,
- 0.2 mg/mL to 40 mg/mL of caffeine,
- 0.04 mg/mL to 20 mg/mL of ashwagandha (Withania somnifera) extract,
- 0.04 mg/mL to 20 mg/mL of milk thistle (Silybum marianum) extract,
- 0.04 mg/mL to 20 mg/mL of willow (Salix alba) extract,
- 0.04 μg/mL to 8 μg/mL of vitamin B12,
- 0.04 mg/mL to 6 mg/mL of vitamin B6,
- 0.04 mg/mL to 4 mg/mL of vitamin B l,
- 10 mg/mL to 400 mg/mL of fructose,
and optionally one or more excipients, in a physiologically acceptable carrier.
2. The food supplement according to claim 1, comprising 10 mg/mL of creatine.
3. The food supplement according to claim 1 or 2, comprising 10 mg/mL of taurine.
4. The food supplement according to any one of the preceding claims, comprising 8 mg/mL of caffeine.
5. The food supplement according to any one of the preceding claims, comprising 1.6 mg/mL of ashwagandha (Withania somnifera) extract.
6. The food supplement according to any one of the preceding claims, comprising 0.2 mg/mL of milk thistle (Silybum marianum) extract.
7. The food supplement according to any one of the preceding claims, comprising 0.4 mg/mL of willow (Salix alba) extract.
8. The food supplement according to any one of the preceding claims,
comprising 0.6 μg/mL of vitamin B12.
9. The food supplement according to any one of the preceding claims, comprising 168 μg/mL of vitamin B6.
10. The food supplement according to any one of the preceding claims, comprising 99 μg/mL of vitamin B 1.
11. The food supplement according to any one of the preceding claims, comprising 200 mg/mL of fructose.
12. The food supplement according to any one of the preceding claims, comprising:
- 10 mg/mL of creatine,
- 10 mg/mL of taurine,
- 8 mg/mL of caffeine,
- 1.6 mg/mL of ashwagandha (Withania somnifera) extract, of which 0.08 mg/mL withanolides,
- 0.2 mg/mL of milk thistle (Silybum marianum) extract, of which
0.16 mg/mL silymarin,
- 0.4 mg/mL of willow (Salix alba) extract, of which 0.06 mg/mL salicin,
- 0.6 μg/mL of vitamin B12,
- 168 μg/mL of vitamin B6,
- 99 μg/mL of vitamin B 1 ,
- 200 mg/mL of fructose, and
- excipients consisting of a combination of an aroma, xanthan gum, potassium sorbate, sodium benzoate, sucralose and steviol glycosides,
in osmotic water.
13. The food supplement according to any one of claims 1 to 12 for use in the prevention and treatment of the effects of a hangover.
14. The food supplement for use according to claim 13, wherein the hangover effects are selected from the group consisting of tiredness, headache, nausea, difficulty concentrating, sensitivity to light and noise, and insomnia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18800050.9A EP3700358A1 (en) | 2017-10-23 | 2018-10-23 | Energizing food supplement and use thereof |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102017000119556 | 2017-10-23 | ||
| IT102017000119556A IT201700119556A1 (en) | 2017-10-23 | 2017-10-23 | Energizing food supplement and its use. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2019081468A1 true WO2019081468A1 (en) | 2019-05-02 |
Family
ID=61257013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2018/078969 WO2019081468A1 (en) | 2017-10-23 | 2018-10-23 | Energizing food supplement and use thereof |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP3700358A1 (en) |
| IT (1) | IT201700119556A1 (en) |
| WO (1) | WO2019081468A1 (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005094862A1 (en) * | 2004-03-23 | 2005-10-13 | Lifeline Nutraceuticals Corporation | Compositions and method for alleviating inflammation and oxidative stress in a mammal |
| US20080020071A1 (en) * | 2005-07-22 | 2008-01-24 | Diaz Victor H | Composition including superoxide dismutase and prickly-pear cactus for minimizing and preventing hangovers |
| WO2008021861A2 (en) * | 2006-08-09 | 2008-02-21 | Evan Hays | Rehydration beverage |
| WO2008115563A1 (en) * | 2007-03-19 | 2008-09-25 | University Of Florida Research Foundation, Inc. | Liquid nutrient composition for improving performance |
| WO2010118405A2 (en) * | 2009-04-10 | 2010-10-14 | Belli Bevies, Llc | Compositions and methods for reducing hangover symptoms |
| WO2011037618A2 (en) * | 2009-09-23 | 2011-03-31 | Todd Ehrlich | Dietary supplements in beverages or other forms, and methods of use and production |
| US20130323323A1 (en) * | 2012-05-31 | 2013-12-05 | David T. Colina | Therapeutic Method and Associated Compound for Augmenting the Liver's Metabolization of Oxygen-Modified Toxins |
| KR20140070470A (en) * | 2012-11-30 | 2014-06-10 | 주식회사유한양행 | Composition for relieving and preventing hangover comprising Dendropanax morbifera extract |
-
2017
- 2017-10-23 IT IT102017000119556A patent/IT201700119556A1/en unknown
-
2018
- 2018-10-23 WO PCT/EP2018/078969 patent/WO2019081468A1/en unknown
- 2018-10-23 EP EP18800050.9A patent/EP3700358A1/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005094862A1 (en) * | 2004-03-23 | 2005-10-13 | Lifeline Nutraceuticals Corporation | Compositions and method for alleviating inflammation and oxidative stress in a mammal |
| US20080020071A1 (en) * | 2005-07-22 | 2008-01-24 | Diaz Victor H | Composition including superoxide dismutase and prickly-pear cactus for minimizing and preventing hangovers |
| WO2008021861A2 (en) * | 2006-08-09 | 2008-02-21 | Evan Hays | Rehydration beverage |
| WO2008115563A1 (en) * | 2007-03-19 | 2008-09-25 | University Of Florida Research Foundation, Inc. | Liquid nutrient composition for improving performance |
| WO2010118405A2 (en) * | 2009-04-10 | 2010-10-14 | Belli Bevies, Llc | Compositions and methods for reducing hangover symptoms |
| WO2011037618A2 (en) * | 2009-09-23 | 2011-03-31 | Todd Ehrlich | Dietary supplements in beverages or other forms, and methods of use and production |
| US20130323323A1 (en) * | 2012-05-31 | 2013-12-05 | David T. Colina | Therapeutic Method and Associated Compound for Augmenting the Liver's Metabolization of Oxygen-Modified Toxins |
| KR20140070470A (en) * | 2012-11-30 | 2014-06-10 | 주식회사유한양행 | Composition for relieving and preventing hangover comprising Dendropanax morbifera extract |
Also Published As
| Publication number | Publication date |
|---|---|
| IT201700119556A1 (en) | 2019-04-23 |
| EP3700358A1 (en) | 2020-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10369182B2 (en) | Compositions and methods for treating insomnia and other sleep related disorders | |
| US20090110674A1 (en) | Health supplement | |
| US20190262414A1 (en) | Natural formulation for treating hangover | |
| US20080102137A1 (en) | Composition and method for etiological treatment and prevention of diseases and/or complications associated with chronic glucose metabolism destabilization | |
| US20090068281A1 (en) | Composition, Functional Food and Pharmaceutical Composition for Improvement in Obesity | |
| CN104223107B (en) | A kind of health products of liver-protecting and alcoholism-relieving toxin expelling | |
| US20060286181A1 (en) | Diet supplements for causing fast weight loss, improving daytime energy, promoting nighttime relaxation and sleep, controlling appetite and/or increasing metabolism | |
| AU2019203595B2 (en) | Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (HMB) for decreasing fat mass | |
| EP2859896B1 (en) | Pharmaceutical compositions for the treatment of muscular disorders | |
| EP2303297B1 (en) | Water-soluble extracts of artemisia dracunculus (tarragon) for improvement of glucose metabolism | |
| FR3080989A1 (en) | LIQUID COMPOSITION COMPRISING AN EXTRACT OF CASSIS LEAVES AND CONCENTRATED APPLE JUICE | |
| US20120020947A1 (en) | Compositions and methods for increasing lean muscle mass after exercise | |
| CN113040393A (en) | Nutritional formula for intervening anxiety and sleep disorder | |
| US20210338757A1 (en) | Dietary supplements for inhibiting pde5 and increasing cgmp levels | |
| WO2008140064A1 (en) | Nutrient composition for prevention and amelioration of lifestyle-related disease | |
| US6932987B1 (en) | Chemical composition and method for enhancing metabolism | |
| EP3700358A1 (en) | Energizing food supplement and use thereof | |
| US20150045432A1 (en) | Dietary supplement comprising amino acids in a palatable liquid formulation that promotes restful sleep, recovery from stress and exercise and strengthens the immune system | |
| US20200214978A1 (en) | Functional chewing gum comprising phytonutrients and adaptogenic herbs | |
| US20150328176A1 (en) | Composition for treatment of neurodegenerative disease | |
| Klatz | The Official Anti-Aging Revolution: Stop the Clock Time is on Your Side for a Younger, Stronger, Happier You | |
| RU2436415C2 (en) | Composition of biologically active substances based on betulin with regulated rate of releasing components for reducing degree of alcohol intoxication, preventing and relieving alcohol intoxication and alcohol withdrawal syndrome | |
| FR2916637A1 (en) | Composition, useful to prepare functional food/food supplement to prevent e.g. chronic disorder of alcoholism, comprises extract mixture of five plants comprising German Chamomile, Melissa, Horsetail, Milk Thistle, Echinacea, and excipient | |
| CN110063977A (en) | A kind of Radix Codonopsis, the compound electuary of sea-buckthorn and its application | |
| US10105347B2 (en) | Sphaeranthus indicus derived ingredients and their compositions for enhancing physical performance and energy levels |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18800050 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2018800050 Country of ref document: EP Effective date: 20200525 |